MediWound (MDWD) Stock Forecast, Price Target & Predictions
MDWD Stock Forecast
MediWound stock forecast is as follows: an average price target of $27.25 (represents a 47.06% upside from MDWD’s last price of $18.53) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
MDWD Price Target
The average price target for MediWound (MDWD) is $27.25 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $23.00. This represents a potential 47.06% upside from MDWD's last price of $18.53.
MDWD Analyst Ratings
According to 3 Wall Street analysts, MediWound's rating consensus is 'Buy'. The analyst rating breakdown for MDWD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MediWound Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 29, 2024 | Francois Brisebois | Oppenheimer | $36.00 | $16.01 | 124.86% | 94.28% |
| Jan 04, 2023 | - | H.C. Wainwright | $23.00 | $13.29 | 73.06% | 24.12% |
| Dec 30, 2022 | - | Cowen & Co. | $25.00 | $13.49 | 85.32% | 34.92% |
| Dec 22, 2022 | - | Maxim Group | $25.00 | $11.01 | 127.07% | 34.92% |
| Nov 16, 2022 | - | H.C. Wainwright | $0.79 | $0.24 | 229.34% | -95.76% |
The latest MediWound stock forecast, released on May 29, 2024 by Francois Brisebois from Oppenheimer, set a price target of $36.00, which represents a 124.86% increase from the stock price at the time of the forecast ($16.01), and a 94.28% increase from MDWD last price ($18.53).
MediWound Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $36.00 |
| Last Closing Price | $18.53 | $18.53 | $18.53 |
| Upside/Downside | -100.00% | -100.00% | 94.28% |
In the current month, the average price target of MediWound stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MediWound's last price of $18.53. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 17, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 05, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 29, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Dec 30, 2022 | Cowen & Co. | Outperform | Outperform | Hold |
| Dec 22, 2022 | Maxim Group | - | Buy | Initialise |
| Dec 21, 2022 | Oppenheimer | Outperform | Outperform | Hold |
MediWound's last stock rating was published by Cowen & Co. on Sep 17, 2024. The company gave MDWD a "Buy" rating, the same as its previous rate.
MediWound Financial Forecast
MediWound Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.80M | $11.62M | $5.80M | $4.67M | $4.41M | $5.49M | $6.37M | $6.06M | $5.85M | $6.67M | $6.63M | $4.03M | $4.44M | $5.44M | $5.14M |
| Avg Forecast | $10.20M | $9.62M | $8.26M | $7.24M | $8.91M | $7.37M | $6.24M | $5.82M | $7.82M | $6.01M | $5.05M | $4.68M | $5.33M | $4.75M | $4.18M | $5.16M | $6.60M | $4.60M | $5.28M | $4.29M | $5.54M | $5.67M | $5.63M | $5.43M | $5.60M | $5.79M | $4.97M | $4.05M | $4.08M | $2.20M |
| High Forecast | $10.52M | $9.93M | $8.52M | $7.47M | $9.19M | $7.60M | $6.44M | $6.00M | $8.06M | $6.20M | $5.21M | $4.83M | $5.77M | $4.90M | $4.31M | $5.32M | $6.81M | $4.75M | $5.28M | $4.55M | $5.86M | $6.00M | $5.96M | $5.75M | $5.93M | $6.13M | $5.26M | $4.29M | $4.32M | $2.33M |
| Low Forecast | $9.67M | $9.13M | $7.83M | $6.87M | $8.45M | $6.99M | $5.92M | $5.52M | $7.41M | $5.70M | $4.79M | $4.44M | $4.60M | $4.50M | $3.96M | $4.89M | $6.26M | $4.37M | $5.28M | $4.07M | $5.25M | $5.38M | $5.34M | $5.15M | $5.31M | $5.50M | $4.71M | $3.84M | $3.87M | $2.09M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 12 | 8 | 8 | 13 | 7 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.74% | 1.76% | 1.26% | 0.88% | 1.03% | 0.99% | 1.12% | 1.08% | 1.08% | 1.19% | 1.14% | 0.81% | 1.10% | 1.33% | 2.34% |
MediWound's average Quarter revenue forecast for Jun 23 based on 2 analysts is $4.18M, with a low forecast of $3.96M, and a high forecast of $4.31M. MDWD's average Quarter revenue forecast represents a 10.03% increase compared to the company's last Quarter revenue of $3.80M (Mar 23).
MediWound EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 12 | 8 | 8 | 13 | 7 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-4.06M | $-8.77M | $-3.17M | $-3.33M | $-2.96M | $-4.64M | $-2.55M | $-2.46M | $-1.64M | $-1.77M | $-1.13M | $-2.44M | $-1.70M | $-3.51M | $-154.00K |
| Avg Forecast | $-3.49M | $-3.29M | $-2.82M | $-2.48M | $-3.05M | $-2.52M | $-2.14M | $-1.99M | $-2.67M | $-2.06M | $-1.73M | $-4.31M | $-1.82M | $-1.62M | $-1.43M | $-3.41M | $-2.26M | $-3.02M | $-1.81M | $-2.69M | $-1.89M | $-2.75M | $-2.23M | $-1.79M | $-2.32M | $-2.76M | $-3.48M | $-3.32M | $-2.47M | $-267.96K |
| High Forecast | $-3.31M | $-3.12M | $-2.68M | $-2.35M | $-2.89M | $-2.39M | $-2.03M | $-1.89M | $-2.54M | $-1.95M | $-1.64M | $-3.45M | $-1.57M | $-1.54M | $-1.36M | $-2.73M | $-2.14M | $-2.42M | $-1.81M | $-2.15M | $-1.80M | $-2.20M | $-1.79M | $-1.43M | $-1.85M | $-2.21M | $-2.79M | $-2.66M | $-1.97M | $-214.37K |
| Low Forecast | $-3.60M | $-3.40M | $-2.91M | $-2.56M | $-3.15M | $-2.60M | $-2.20M | $-2.05M | $-2.76M | $-2.12M | $-1.78M | $-5.17M | $-1.97M | $-1.67M | $-1.48M | $-4.09M | $-2.33M | $-3.62M | $-1.81M | $-3.23M | $-2.01M | $-3.29M | $-2.68M | $-2.14M | $-2.78M | $-3.31M | $-4.18M | $-3.99M | $-2.96M | $-321.55K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.19% | 3.88% | 1.05% | 1.85% | 1.10% | 2.45% | 0.93% | 1.10% | 0.92% | 0.76% | 0.41% | 0.70% | 0.51% | 1.42% | 0.57% |
undefined analysts predict MDWD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than MediWound's previous annual EBITDA (undefined) of $NaN.
MediWound Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 12 | 8 | 8 | 13 | 7 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.69M | $-7.46M | $-4.20M | $-4.35M | $-3.59M | $-4.16M | $-3.35M | $-3.19M | $-3.78M | $-1.07M | $-2.35M | $-3.49M | $-2.72M | $-5.00M | $-450.00K |
| Avg Forecast | - | - | - | - | $-6.03M | $-5.94M | $-5.89M | $-5.80M | $-5.15M | $-4.20M | $-3.90M | $-5.22M | $-2.44M | $-4.11M | $-3.80M | $-4.13M | $-2.90M | $-3.96M | $-6.25M | $-3.26M | $-9.66M | $-3.60M | $-2.90M | $-3.11M | $-2.27M | $-2.48M | $-3.35M | $-3.34M | $-2.41M | $-361.92K |
| High Forecast | - | - | - | - | $-5.63M | $-5.54M | $-5.50M | $-5.41M | $-4.80M | $-4.02M | $-3.64M | $-4.18M | $741.34K | $-3.83M | $-3.55M | $-3.30M | $-2.71M | $-3.17M | $-6.25M | $-2.61M | $-9.02M | $-2.88M | $-2.32M | $-2.49M | $-1.81M | $-1.98M | $-2.68M | $-2.67M | $-1.93M | $-289.54K |
| Low Forecast | - | - | - | - | $-6.28M | $-6.18M | $-6.13M | $-6.04M | $-5.36M | $-4.29M | $-4.06M | $-6.27M | $-4.24M | $-4.27M | $-3.96M | $-4.95M | $-3.02M | $-4.76M | $-6.25M | $-3.92M | $-10.40M | $-4.32M | $-3.49M | $-3.73M | $-2.72M | $-2.97M | $-4.02M | $-4.01M | $-2.89M | $-434.30K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 2.57% | 1.06% | 0.70% | 1.10% | 0.43% | 0.93% | 1.10% | 1.22% | 0.47% | 0.95% | 1.04% | 0.81% | 2.07% | 1.24% |
MediWound's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MDWD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
MediWound SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 12 | 8 | 8 | 13 | 7 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.09M | $2.69M | $3.06M | $2.29M | $2.34M | $2.36M | $2.44M | $2.60M | $2.10M | $2.38M | $2.17M | $2.31M | $1.72M | $2.82M | $1.96M |
| Avg Forecast | $4.29M | $4.04M | $3.47M | $3.04M | $3.75M | $3.10M | $2.62M | $2.45M | $3.29M | $2.52M | $2.12M | $3.40M | $2.24M | $1.99M | $1.76M | $2.69M | $2.77M | $2.89M | $2.22M | $2.12M | $2.33M | $2.63M | $2.36M | $2.29M | $3.26M | $2.82M | $4.25M | $1.70M | $3.46M | $924.93K |
| High Forecast | $4.42M | $4.17M | $3.58M | $3.14M | $3.87M | $3.20M | $2.71M | $2.52M | $3.39M | $2.60M | $2.19M | $4.08M | $2.43M | $2.06M | $1.81M | $3.22M | $2.86M | $3.47M | $2.22M | $2.55M | $2.46M | $3.16M | $2.84M | $2.74M | $3.91M | $3.39M | $5.10M | $1.80M | $4.15M | $979.14K |
| Low Forecast | $4.06M | $3.84M | $3.29M | $2.89M | $3.55M | $2.94M | $2.49M | $2.32M | $3.12M | $2.39M | $2.01M | $2.72M | $1.93M | $1.89M | $1.67M | $2.15M | $2.63M | $2.31M | $2.22M | $1.70M | $2.21M | $2.10M | $1.89M | $1.83M | $2.61M | $2.26M | $3.40M | $1.62M | $2.77M | $877.61K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 0.97% | 1.06% | 1.03% | 1.10% | 1.01% | 0.93% | 1.10% | 0.92% | 0.73% | 0.77% | 0.54% | 1.01% | 0.82% | 2.11% |
MediWound's average Quarter SG&A projection for Jun 23 is $1.76M, based on 2 Wall Street analysts, with a range of $1.67M to $1.81M. The forecast indicates a -43.10% fall compared to MDWD last annual SG&A of $3.09M (Mar 23).
MediWound EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 12 | 8 | 8 | 13 | 7 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-1.18 | $-0.88 | $-0.92 | $-0.87 | $-0.02 | $-0.84 | $-0.84 | $-0.70 | $-0.42 | $-0.49 | $-0.77 | $-0.63 | $-0.91 | $-0.07 |
| Avg Forecast | - | - | - | - | $-0.65 | $-0.64 | $-0.64 | $-0.63 | $-0.56 | $-0.45 | $-0.42 | $-0.41 | $-0.26 | $-0.44 | $-0.41 | $-0.30 | $-0.31 | $-0.70 | $-0.68 | $-0.76 | $-1.05 | $-0.90 | $-0.78 | $-0.78 | $-0.79 | $-0.67 | $-0.84 | $-1.00 | $-0.73 | $-1.01 |
| High Forecast | - | - | - | - | $-0.61 | $-0.60 | $-0.59 | $-0.58 | $-0.52 | $-0.43 | $-0.39 | $-0.38 | $0.08 | $-0.41 | $-0.38 | $-0.28 | $-0.29 | $-0.65 | $-0.68 | $-0.71 | $-0.98 | $-0.84 | $-0.73 | $-0.73 | $-0.74 | $-0.63 | $-0.78 | $-0.93 | $-0.69 | $-0.94 |
| Low Forecast | - | - | - | - | $-0.68 | $-0.67 | $-0.66 | $-0.65 | $-0.58 | $-0.46 | $-0.44 | $-0.42 | $-0.46 | $-0.46 | $-0.43 | $-0.32 | $-0.33 | $-0.73 | $-0.68 | $-0.81 | $-1.13 | $-0.97 | $-0.84 | $-0.84 | $-0.85 | $-0.72 | $-0.90 | $-1.07 | $-0.79 | $-1.09 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.44% | 3.78% | 1.26% | 1.36% | 1.15% | 0.02% | 0.93% | 1.07% | 0.90% | 0.53% | 0.73% | 0.92% | 0.63% | 1.24% | 0.07% |
According to undefined Wall Street analysts, MediWound's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MDWD previous annual EPS of $NaN (undefined).
MediWound Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| LYEL | Lyell Immunopharma | $1.39 | $9.50 | 583.45% | Hold |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| NKTX | Nkarta | $5.39 | $21.60 | 300.74% | Buy |
| SANA | Sana Bio | $4.30 | $12.00 | 179.07% | Buy |
| STRO | Sutro Biopharma | $4.01 | $10.80 | 169.33% | Buy |
| MLYS | Mineralys Therapeutics | $11.98 | $30.00 | 150.42% | Buy |
| REPL | Replimune Group | $11.03 | $24.20 | 119.40% | Buy |
| OCUL | Ocular Therapeutix | $8.76 | $17.50 | 99.77% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.06 | $36.00 | 99.34% | Buy |
| KROS | Keros Therapeutics | $55.04 | $105.00 | 90.77% | Buy |
| SWTX | SpringWorks Therapeutics | $35.42 | $67.33 | 90.09% | Buy |
| FHTX | Foghorn Therapeutics | $9.84 | $18.00 | 82.93% | Buy |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| MRUS | Merus | $50.10 | $77.86 | 55.41% | Buy |
| MDWD | MediWound | $18.53 | $27.25 | 47.06% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| RNA | Avidity Biosciences | $42.19 | $50.00 | 18.51% | Buy |
| VCYT | Veracyte | $34.32 | $26.00 | -24.24% | Buy |
MDWD Forecast FAQ
Is MediWound a good buy?
Yes, according to 3 Wall Street analysts, MediWound (MDWD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of MDWD's total ratings.
What is MDWD's price target?
MediWound (MDWD) average price target is $27.25 with a range of $23 to $36, implying a 47.06% from its last price of $18.53. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MediWound stock go up soon?
According to Wall Street analysts' prediction for MDWD stock, the company can go up by 47.06% (from the last price of $18.53 to the average price target of $27.25), up by 94.28% based on the highest stock price target, and up by 24.12% based on the lowest stock price target.
Can MediWound stock reach $30?
MDWD's highest twelve months analyst stock price target of $36 supports the claim that MediWound can reach $30 in the near future.
What are MediWound's analysts' financial forecasts?
MediWound's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $28.34M (high $29.24M, low $26.88M), average EBITDA is $-9.697M (high $-9.197M, low $-10.004M), average net income is $-23.662M (high $-22.076M, low $-24.635M), average SG&A $11.91M (high $12.29M, low $11.3M), and average EPS is $-2.55 (high $-2.379, low $-2.655). MDWD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $35.31M (high $36.43M, low $33.49M), average EBITDA is $-12.082M (high $-11.459M, low $-12.464M), average net income is $0 (high $0, low $0), average SG&A $14.84M (high $15.31M, low $14.08M), and average EPS is $0 (high $0, low $0).
Did the MDWD's actual financial results beat the analysts' financial forecasts?
Based on MediWound's last annual report (Dec 2022), the company's revenue was $26.5M, beating the average analysts forecast of $20.77M by 27.55%. Apple's EBITDA was $-9.331M, missing the average prediction of $-9.777M by -4.56%. The company's net income was $-19.599M, beating the average estimation of $-16.374M by 19.70%. Apple's SG&A was $10.37M, beating the average forecast of $10.01M by 3.62%. Lastly, the company's EPS was $-3.93, beating the average prediction of $-2.445 by 60.73%. In terms of the last quarterly report (Mar 2023), MediWound's revenue was $3.8M, missing the average analysts' forecast of $5.16M by -26.38%. The company's EBITDA was $-4.061M, beating the average prediction of $-3.407M by 19.18%. MediWound's net income was $-3.693M, missing the average estimation of $-4.127M by -10.52%. The company's SG&A was $3.09M, beating the average forecast of $2.69M by 14.95%. Lastly, the company's EPS was $-0.44, beating the average prediction of $-0.305 by 44.26%